Xin Hu

Xin Hu

Auto-generated profile, based on publicly available information

Xin Hu

Department of Radiation Oncology, Emory University School of Medicine, Atlanta, GA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2017 in Cancer
Verified
Journal Article
Open access
PDF file
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan
XHXin Hu
Xin Hu
JLJessica B. Long
Jessica B. Long
RWRong Wang
Rong Wang
XMXiaomei Ma
Xiaomei Ma
ADAmy J. Davidoff
Amy J. Davidoff
BACKGROUND: Despite the approval of azacitidine in 2004 and the approval of decitabine in 2006 in the United States for chronic myelomonocytic leukemia (CMML), the overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear.METHODS: Older adults (age ≥ 66 years) who had been diagnosed with CMML from 2001 to 2011 were selected from the Surveillance, Epidemiology, and End Results–Medicare database, and propensity score matching was used to match patients who had been diagnosed after HMA approval (2007‐2011) and had received HMA treatment with patients diagnosed before HMA approval (2001‐2003). Cox proportional hazards models with the matched sample were used to assess the change in OS. A second matched cohort of patients who did not receive HMA after approval and patients diagnosed before HMA approval was used to evaluate survival change attributable to other potential differences between the 2 time periods, such as improved supportive care.RESULTS: Among 1378 older adults diagnosed with CMML, the median OS was 13 months, and 18.8% received HMAs. In the primary matched analysis, with 225 HMA users diagnosed in 2007‐2011 and 395 patients diagnosed in 2001‐2003, the median OS times were 17 and 11 months, respectively (hazard ratio, 0.72; 95% confidence interval [CI], 0.58‐0.91; P = .005). In a secondary analysis, the risk of death did not differ between 395 propensity score–matched HMA nonusers diagnosed in 2007‐2011 and 484 patients diagnosed in 2001‐2003 (hazard ratio, 1.09; 95% CI, 0.91‐1.32; P = .34).CONCLUSIONS: Despite limited evidence, HMAs are commonly used to treat older CMML patients. The use of HMAs was associated with a 28% reduction in the risk of death in adjusted analyses. Improvements in supportive care do not appear to account for temporal improvements in OS. Cancer 2017;123:3754–3762. © 2017 American Cancer Society

1 October 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan
XHXin Hu
Xin Hu
WZWeiwei Zhu
Weiwei Zhu
MSMaximilian Stahl
Maximilian Stahl
RWRong Wang
Rong Wang
ADAmy J. Davidoff
Amy J. Davidoff
Population level survival of patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) is inferior to clinical trials. Using SEER-Medicare data, we identified 2086 MDS patients diagnosed in 2004–13, aged ≥66 years at diagnosis, and receiving ≥1 HMA cycle after 2005. We used multivariate logistic regression and Cox proportional hazards models to assess the impact of provider experience on persistent HMA therapy and overall survival (OS), respectively. Median number of HMA cycles was 4 and median OS was 10 months. Thirty-two percent of patients were treated by providers with ≥1 prior HMA initiation in the last 2 years and were more likely to receive ≥4 cycles of HMA therapy (OR = 1.29, 95% CI = 1.06–1.57; p = .01). No significant association was found between MDS or HMA initiation volume and survival. In conclusion, while HMA initiation volume was associated with persistent HMA treatment, neither MDS nor HMA initiation volumes were associated with OS in older MDS patients.

18 October 2022 in Cancer Medicine
Verified
Journal Article
Open access
IGIlana Graetz
Ilana Graetz
XHXin Hu
Xin Hu
ACAndrea N. Curry
Andrea N. Curry
ARAndrew Robles
Andrew Robles
GVGregory A. Vidal
Gregory A. Vidal
LSLee S. Schwartzberg
Lee S. Schwartzberg
Background: Cancer treatment requires substantial demands on patients and their caregivers. Mobile apps can provide support for self‐management during oncology treatment, but few have been rigorously evaluated.Methods: A 3‐month randomized controlled trial was conducted at a large cancer center to evaluate the efficacy of an app (LivingWith®) that provides self‐management support during cancer treatment on quality of life and health care utilization. Patients in chemotherapy treatment were randomized into the intervention (n = 113) and control group (n = 111). Intervention group participants agreed to use the app weekly for 3 months, and all participants completed a survey at enrollment and after 3 months to evaluate changes in quality of life and health care utilization.Results: Retention rate was 75.4% with 169 participants completing the follow‐up survey. The intervention group reported 0.74 fewer medical office visits (p = 0.043) and 0.24 fewer visits with a mental health professional (p = 0.061) during the 3 and month intervention compared with controls. There were no significant changes by study group in quality of life, or emergency room and urgent care visits. Among intervention participants, 75.3% reported using the app and on average, used it 11.7 times during the 3‐month intervention. Reasons for not using the app among intervention participants included lack of time, lack of interest in apps, and usability challenges.Conclusions and Relevance: Apps are inexpensive and scalable tools that can provide additional support for individuals coping with complex cancer treatments. This trial provides evidence that a well‐designed oncology support app used during chemotherapy resulted in fewer clinic visits. Still, nearly a quarter of participants randomized to the intervention arm reported never using the app due to personal preference and usability challenges, which points to future opportunities for calibrating target user population and improving user‐centered design.Clinicaltrials.gov identifier: NCT04331678.

26 December 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
ADAmy J. Davidoff
Amy J. Davidoff
XHXin Hu
Xin Hu
JBJan Bewersdorf
Jan Bewersdorf
RWRong Wang
Rong Wang
NPNikolai A. Podoltsev
Nikolai A. Podoltsev
Amer M. ZeidanAmer M. Zeidan
Amer M. Zeidan
Hypomethylating agents (HMA) showed overall survival (OS) benefits in patients with higher-risk myelodysplastic syndromes (HR-MDS) in clinical trials. We conducted a retrospective cohort study of Surveillance, Epidemiology, and End Results (SEER)-Medicare data of patients ≥66 years diagnosed with refractory anemia with excess blasts (RAEB), a proxy for HR-MDS, in 01/2001–04/2004 (pre-period) or 01/2006–12/2011 (post-period). Association between post-period diagnosis and OS was examined using propensity scores (PS)-matched samples. Among 1876 RAEB patients, median OS was 9 months and 30.8% received HMAs (3.6% in pre-period; 43.0% in post-period) with no association between post-period diagnosis and OS. In the top PS quartile, post-period diagnosis was associated with a 74% lower risk of death (Hazard ratio [HR] = 0.26, 95%-CI: 0.10–0.69, p = 0.007), while outcomes were worse in the lowest PS quartile (HR = 2.80, 95%-CI: 1.06–7.36, p = 0.037). HMA lead to a 3-month OS benefit for patients most likely to receive HMA but not for unselected RAEB cohort.

28 April 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
QYQianying Yuan
Qianying Yuan
ABAbdul Basit
Abdul Basit
WLWenhua Liang
Wenhua Liang
RQRihao Qu
Rihao Qu
YLYi Luan
Yi Luan
DWDianqing Wu
Dianqing Wu
MAP3K inhibition attenuates acute lung injuries in mice and reduced edema in lung transplantation recipients.

11 March 2024 in Journal of Pain and Symptom Management
Verified
Journal Article
Closed access
XHXin Hu
Xin Hu
CJChangchuan Jiang
Changchuan Jiang
QFQinjin Fan
Qinjin Fan
KSKewei Sylvia Shi
Kewei Sylvia Shi
RPRavi B. Parikh
Ravi B. Parikh
XHXuesong Han
Xuesong Han